<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:ynews="http://news.yahoo.com/rss/">
    <channel>
        <title>Nova Reader - Subject</title>
        <link>https://www.novareader.co</link>
        <description>Default RSS Feed</description>
        <language>en-us</language>
        <copyright>Newgen KnowledgeWorks</copyright>
        <item>
            <title><![CDATA[Rational engineering of a modular bacterial CRISPR–Cas activation platform with expanded target range]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766072830486-3ac37407-1322-4396-bdb9-db9a5c795b7e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkab211</link>
            <description><![CDATA[<p class="para" id="N65541">CRISPR–Cas activator (CRISPRa) systems that selectively turn on transcription of a target gene are a potentially transformative technology for programming cellular function. While in eukaryotes versatile CRISPRa systems exist, in bacteria these systems suffer from a limited ability to activate different genes due to strict distance-dependent requirements of functional target binding sites, and require greater customization to optimize performance in different genetic and cellular contexts. To address this, we apply a rational protein engineering approach to create a new CRISPRa platform that is highly modular to allow for easy customization and has increased targeting flexibility through harnessing engineered Cas proteins. We first demonstrate that transcription activation domains can be recruited by CRISPR–Cas through noncovalent protein-protein interactions, which allows each component to be encoded on separate and easily interchangeable plasmid elements. We then exploit this modularity to rapidly screen a library of different activation domains, creating new systems with distinct regulatory properties. Furthermore, we demonstrate that by harnessing a library of circularly permuted Cas proteins, we can create CRISPRa systems that have different target binding site requirements, which together, allow for expanded target range.</p>]]></description>
            <pubDate><![CDATA[2021-04-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Choice of fluorophore affects dynamic DNA nanostructures]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766037552707-a1671b78-73f0-4df9-bd2f-8fd0c1cbdb50/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkab201</link>
            <description><![CDATA[<p class="para" id="N65541">The ability to dynamically remodel DNA origami structures or functional nanodevices is highly desired in the field of DNA nanotechnology. Concomitantly, the use of fluorophores to track and validate the dynamics of such DNA-based architectures is commonplace and often unavoidable. It is therefore crucial to be aware of the side effects of popular fluorophores, which are often exchanged without considering the potential impact on the system. Here, we show that the choice of fluorophore can strongly affect the reconfiguration of DNA nanostructures. To this end, we encapsulate a triple-stranded DNA (tsDNA) into water-in-oil compartments and functionalize their periphery with a single-stranded DNA handle (ssDNA). Thus, the tsDNA can bind and unbind from the periphery by reversible opening of the triplex and subsequent strand displacement. Using a combination of experiments, molecular dynamics (MD) simulations, and reaction-diffusion modelling, we demonstrate for 12 different fluorophore combinations that it is possible to alter or even inhibit the DNA nanostructure formation—without changing the DNA sequence. Besides its immediate importance for the design of pH-responsive switches and fluorophore labelling, our work presents a strategy to precisely tune the energy landscape of dynamic DNA nanodevices.</p>]]></description>
            <pubDate><![CDATA[2021-03-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[MiniCAFE, a CRISPR/Cas9-based compact and potent transcriptional activator, elicits gene expression <i>in vivo</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766037239636-84640a7b-5b3b-422c-aa96-4b97a6f90fc9/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkab174</link>
            <description><![CDATA[<p class="para" id="N65541">CRISPR-mediated gene activation (CRISPRa) is a promising therapeutic gene editing strategy without inducing DNA double-strand breaks (DSBs). However, <i>in vivo</i> implementation of these CRISPRa systems remains a challenge. Here, we report a compact and robust miniCas9 activator (termed miniCAFE) for <i>in vivo</i> activation of endogenous target genes. The system relies on recruitment of an engineered minimal nuclease-null Cas9 from <i>Campylobacter jejuni</i> and potent transcriptional activators to a target locus by a single guide RNA. It enables robust gene activation in human cells even with a single DNA copy and is able to promote lifespan of <i>Caenorhabditis elegans</i> through activation of longevity-regulating genes. As proof-of-concept, delivered within an all-in-one adeno-associated virus (AAV), miniCAFE can activate Fgf21 expression in the liver and regulate energy metabolism in adult mice. Thus, miniCAFE holds great therapeutic potential against human diseases.</p><p class="para" id="N65542">
<div class="section" id="ga1"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('ga1');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1766037239636-84640a7b-5b3b-422c-aa96-4b97a6f90fc9/assets/gkab174gra1.jpg" alt="Target transcription activation with CjCas9-based gene activators. Three gene activators, SunTag-dCjCas9/VPR, VPR-dCjCas9, and VPR-CjCas9, are developed. Minimization and optimization of VPR-dCjCas9 leads to creation of MiniCAFE, which is able to activate gene expression and induce corresponding phenotypes in C. elegans, mice and human cells."/></div></div><div class="imgeVideoCaption" id="N65544"><div class="captionTitle">Graphical Abstract</div><div class="captionText">                                      Target transcription activation with CjCas9-based gene activators. Three gene activators, SunTag-dCjCas9/VPR, VPR-dCjCas9, and VPR-CjCas9, are developed. Minimization and optimization of VPR-dCjCas9 leads to creation of MiniCAFE, which is able to activate gene expression and induce corresponding phenotypes in C. elegans, mice and human cells.</div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2021-03-22T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Targeted-antibacterial-plasmids (TAPs) combining conjugation and CRISPR/Cas systems achieve strain-specific antibacterial activity]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766020944898-1f93ce3d-bbe5-4035-b217-e2776af55082/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkab126</link>
            <description><![CDATA[<p class="para" id="N65541">The global emergence of drug-resistant bacteria leads to the loss of efficacy of our antibiotics arsenal and severely limits the success of currently available treatments. Here, we developed an innovative strategy based on targeted-antibacterial-plasmids (TAPs) that use bacterial conjugation to deliver CRISPR/Cas systems exerting a strain-specific antibacterial activity. TAPs are highly versatile as they can be directed against any specific genomic or plasmid DNA using the custom algorithm (CSTB) that identifies appropriate targeting spacer sequences. We demonstrate the ability of TAPs to induce strain-selective killing by introducing lethal double strand breaks (DSBs) into the targeted genomes. TAPs directed against a plasmid-born carbapenem resistance gene efficiently resensitise the strain to the drug. This work represents an essential step toward the development of an alternative to antibiotic treatments, which could be used for <i>in situ</i> microbiota modification to eradicate targeted resistant and/or pathogenic bacteria without affecting other non-targeted bacterial species.</p>]]></description>
            <pubDate><![CDATA[2021-02-28T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Small-molecule inhibitors of histone deacetylase improve CRISPR-based adenine base editing]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765948059563-070974ee-b967-4d4c-a5cb-0a85cd37da19/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkab052</link>
            <description><![CDATA[<p class="para" id="N65541">CRISPR-based base editors (BEs) are widely used to induce nucleotide substitutions in living cells and organisms without causing the damaging DNA double-strand breaks and DNA donor templates. Cytosine BEs that induce C:G to T:A conversion and adenine BEs that induce A:T to G:C conversion have been developed. Various attempts have been made to increase the efficiency of both BEs; however, their activities need to be improved for further applications. Here, we describe a fluorescent reporter-based drug screening platform to identify novel chemicals with the goal of improving adenine base editing efficiency. The reporter system revealed that histone deacetylase inhibitors, particularly romidepsin, enhanced base editing efficiencies by up to 4.9-fold by increasing the expression levels of proteins and target accessibility. The results support the use of romidepsin as a viable option to improve base editing efficiency in biomedical research and therapeutic genome engineering.</p>]]></description>
            <pubDate><![CDATA[2021-02-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Ligand-dependent tRNA processing by a rationally designed RNase P riboswitch]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765906252488-d30a5e6d-f4b1-4cf2-8f19-758685127cb5/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1282</link>
            <description><![CDATA[<p class="para" id="N65541">We describe a synthetic riboswitch element that implements a regulatory principle which directly addresses an essential tRNA maturation step. Constructed using a rational <i>in silico</i> design approach, this riboswitch regulates RNase P-catalyzed tRNA 5′-processing by either sequestering or exposing the single-stranded 5′-leader region of the tRNA precursor in response to a ligand. A single base pair in the 5′-leader defines the regulatory potential of the riboswitch both <i>in vitro</i> and <i>in vivo</i>. Our data provide proof for prior postulates on the importance of the structure of the leader region for tRNA maturation. We demonstrate that computational predictions of ligand-dependent structural rearrangements can address individual maturation steps of stable non-coding RNAs, thus making them amenable as promising target for regulatory devices that can be used as functional building blocks in synthetic biology.</p>]]></description>
            <pubDate><![CDATA[2021-01-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[A supernumerary designer chromosome for modular <i>in vivo</i> pathway assembly in <i>Saccharomyces cerevisiae</i>]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765905953242-e5a25479-749a-4af3-be12-a6c4c2c5bd92/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1167</link>
            <description><![CDATA[<p class="para" id="N65541">The construction of microbial cell factories for sustainable production of chemicals and pharmaceuticals requires extensive genome engineering. Using <i>Saccharomyces cerevisiae</i>, this study proposes synthetic neochromosomes as orthogonal expression platforms for rewiring native cellular processes and implementing new functionalities. Capitalizing the powerful homologous recombination capability of <i>S. cerevisiae</i>, modular neochromosomes of 50 and 100 kb were fully assembled <i>de novo</i> from up to 44 transcriptional-unit-sized fragments in a single transformation. These assemblies were remarkably efficient and faithful to their <i>in silico</i> design. Neochromosomes made of non-coding DNA were stably replicated and segregated irrespective of their size without affecting the physiology of their host. These non-coding neochromosomes were successfully used as landing pad and as exclusive expression platform for the essential glycolytic pathway. This work pushes the limit of DNA assembly in <i>S. cerevisiae</i> and paves the way for <i>de novo</i> designer chromosomes as modular genome engineering platforms in <i>S. cerevisiae</i>.</p>]]></description>
            <pubDate><![CDATA[2021-01-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Programmable gene regulation for metabolic engineering using decoy transcription factor binding sites]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765852738711-326e7eac-f0cd-479e-82aa-59eca983d359/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1234</link>
            <description><![CDATA[<p class="para" id="N65541">Transcription factor decoy binding sites are short DNA sequences that can titrate a transcription factor away from its natural binding site, therefore regulating gene expression. In this study, we harness synthetic transcription factor decoy systems to regulate gene expression for metabolic pathways in <i>Escherichia coli</i>. We show that transcription factor decoys can effectively regulate expression of native and heterologous genes. Tunability of the decoy can be engineered via changes in copy number or modifications to the DNA decoy site sequence. Using arginine biosynthesis as a showcase, we observed a 16-fold increase in arginine production when we introduced the decoy system to steer metabolic flux towards increased arginine biosynthesis, with negligible growth differences compared to the wild type strain. The decoy-based production strain retains high genetic integrity; in contrast to a gene knock-out approach where mutations were common, we detected no mutations in the production system using the decoy-based strain. We further show that transcription factor decoys are amenable to multiplexed library screening by demonstrating enhanced tolerance to pinene with a combinatorial decoy library. Our study shows that transcription factor decoy binding sites are a powerful and compact tool for metabolic engineering.</p>]]></description>
            <pubDate><![CDATA[2020-12-24T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Precise and broad scope genome editing based on high-specificity Cas9 nickases]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765847374628-094b7939-d625-4485-947d-823f111bc8b7/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/nar/gkaa1236</link>
            <description><![CDATA[<p class="para" id="N65541">RNA-guided nucleases (RGNs) based on CRISPR systems permit installing short and large edits within eukaryotic genomes. However, precise genome editing is often hindered due to nuclease off-target activities and the multiple-copy character of the vast majority of chromosomal sequences. Dual nicking RGNs and high-specificity RGNs both exhibit low off-target activities. Here, we report that high-specificity Cas9 nucleases are convertible into nicking Cas9<sup>D10A</sup> variants whose precision is superior to that of the commonly used Cas9<sup>D10A</sup> nickase. Dual nicking RGNs based on a selected group of these Cas9<sup>D10A</sup> variants can yield gene knockouts and gene knock-ins at frequencies similar to or higher than those achieved by their conventional counterparts. Moreover, high-specificity dual nicking RGNs are capable of distinguishing highly similar sequences by ‘tiptoeing’ over pre-existing single base-pair polymorphisms. Finally, high-specificity RNA-guided nicking complexes generally preserve genomic integrity, as demonstrated by unbiased genome-wide high-throughput sequencing assays. Thus, in addition to substantially enlarging the Cas9 nickase toolkit, we demonstrate the feasibility in expanding the range and precision of DNA knockout and knock-in procedures. The herein introduced tools and multi-tier high-specificity genome editing strategies might be particularly beneficial whenever predictability and/or safety of genetic manipulations are paramount.</p>]]></description>
            <pubDate><![CDATA[2021-01-04T00:00]]></pubDate>
        </item>
    </channel>
</rss>